<DOC>
	<DOCNO>NCT00004206</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine oxaliplatin fluorouracil treat patient recurrent ovarian cancer .</brief_summary>
	<brief_title>Oxaliplatin Fluorouracil Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy oxaliplatin combination fluorouracil term response rate , time tumor progression , overall survival patient recurrent ovarian cancer . II . Evaluate safety profile combination regimen patient population . OUTLINE : This open label study . Patients receive oxaliplatin IV 2 hour every 2 week fluorouracil IV leucovorin calcium IV weekly . Treatment repeat every 2 week 12 course absence disease progression unacceptable toxicity . Patients stable respond disease follow 1 month 3 month , every 3 month disease relapse survival . PROJECTED ACCRUAL : A total 14-50 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian cancer Must receive least one prior platinum base chemotherapy regimen relapse within 2 year last chemotherapy regimen Evaluable disease Radiology confirmation AND/OR Elevated CA 125 ( least 60 IU/L ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) ( unless document Gilbert 's syndrome ) AST/ALT le 3 time ULN ( less 5 time ULN liver metastasis present ) Renal : Creatinine normal Cardiovascular : No unstable cardiovascular disease Other : No active , uncontrolled infection No significant medical disorder condition would preclude study No malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify Other : At least 30 day since prior investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>